| scholarly article | Q13442814 |
| P356 | DOI | 10.1164/RCCM.200409-1164OC |
| P698 | PubMed publication ID | 15502109 |
| P50 | author | Lynne Murray | Q61905429 |
| P2093 | author name string | Marie D Burdick | |
| Robert M Strieter | |||
| John A Belperio | |||
| Michael P Keane | |||
| Ying Ying Xue | |||
| David A Zisman | |||
| P433 | issue | 3 | |
| P921 | main subject | pulmonary fibrosis | Q32446 |
| microvasculature remodeling | Q6840464 | ||
| P304 | page(s) | 261-268 | |
| P577 | publication date | 2004-10-22 | |
| P1433 | published in | American Journal of Respiratory and Critical Care Medicine | Q4744267 |
| P1476 | title | CXCL11 attenuates bleomycin-induced pulmonary fibrosis via inhibition of vascular remodeling | |
| P478 | volume | 171 |
| Q36542274 | A review of current and novel therapies for idiopathic pulmonary fibrosis |
| Q34882979 | Angiogenesis in interstitial lung diseases: a pathogenetic hallmark or a bystander? |
| Q35179145 | Angiogenic activity of sera from interstitial lung disease patients in relation to pulmonary function |
| Q35120028 | Angiogenic activity of sera from pulmonary tuberculosis patients in relation to IL-12p40 and TNFα serum levels |
| Q33748545 | Anti-asialo GM1 NK cell depleting antibody does not alter the development of bleomycin induced pulmonary fibrosis |
| Q38621453 | Antifibrotic role of vascular endothelial growth factor in pulmonary fibrosis. |
| Q21092158 | BMP-7 does not protect against bleomycin-induced lung or skin fibrosis |
| Q24813072 | CCR2 and CXCR3 agonistic chemokines are differently expressed and regulated in human alveolar epithelial cells type II. |
| Q38763077 | CXCL9 Regulates TGF-β1-Induced Epithelial to Mesenchymal Transition in Human Alveolar Epithelial Cells |
| Q33756881 | CXCR3 Requirement for the Interleukin-13-Mediated Up-Regulation of Interleukin-13Rα2 in Pulmonary Fibroblasts |
| Q37827339 | CXCR3 ligands: redundant, collaborative and antagonistic functions |
| Q34106221 | CXCR3-independent actions of the CXC chemokine CXCL10 in the infarcted myocardium and in isolated cardiac fibroblasts are mediated through proteoglycans |
| Q30426904 | Chemokines as mediators of angiogenesis. |
| Q30438032 | Chemokines as mediators of neovascularization |
| Q30427886 | Chemokines as mediators of tumor angiogenesis and neovascularization |
| Q35967027 | Cytokine-like factor 1 gene expression is enriched in idiopathic pulmonary fibrosis and drives the accumulation of CD4+ T cells in murine lungs: evidence for an antifibrotic role in bleomycin injury |
| Q36888683 | Endostatin, an angiogenesis inhibitor, ameliorates bleomycin-induced pulmonary fibrosis in rats |
| Q27025625 | Evolving genomic approaches to idiopathic pulmonary fibrosis: moving beyond genes |
| Q42654399 | Expressed gene sequence and bioactivity of the IFNgamma-response chemokine CXCL11 of swine and cattle. |
| Q40239051 | Final results of a double-blind, placebo-controlled trial of the antifibrotic efficacy of interferon-gamma1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis |
| Q37175083 | G-protein coupled chemoattractant receptors and cancer |
| Q30439944 | GammadeltaT cells initiate acute inflammation and injury in adenovirus-infected liver via cytokine-chemokine cross talk |
| Q35855118 | Gene expression profiling of familial and sporadic interstitial pneumonia |
| Q41460801 | Gene expression profiling of idiopathic interstitial pneumonias (IIPs): identification of potential diagnostic markers and therapeutic targets. |
| Q38112030 | Growth factors and cytokines in acute lung injury |
| Q24314328 | IP-10 induces dissociation of newly formed blood vessels |
| Q36440438 | Idiopathic pulmonary fibrosis : new concepts in pathogenesis and implications for drug therapy |
| Q58560341 | Inflammatory Signature in Lung Tissues in Patients with Combined Pulmonary Fibrosis and Emphysema |
| Q28506363 | Inhibitor of differentiation 1 promotes endothelial survival in a bleomycin model of lung injury in mice |
| Q35106452 | Integrating mechanisms of pulmonary fibrosis |
| Q37732963 | Kallistatin protects against bleomycin-induced idiopathic pulmonary fibrosis by inhibiting angiogenesis and inflammation |
| Q34195733 | Kinetics of the angiogenic response in lung endothelium following acute inflammatory injury with bleomycin |
| Q33905052 | Lymphatics in idiopathic pulmonary fibrosis: new insights into an old disease |
| Q34560457 | Lymphatics in lymphangioleiomyomatosis and idiopathic pulmonary fibrosis |
| Q37791764 | New pharmacological strategies for the treatment of pulmonary fibrosis |
| Q34903224 | Novel therapeutic approaches for pulmonary fibrosis |
| Q38180825 | Paracrine functions of fibrocytes to promote lung fibrosis |
| Q37115840 | Pathophysiological roles of microvascular alterations in pulmonary inflammatory diseases: possible implications of tumor necrosis factor-alpha and CXC chemokines |
| Q38111715 | Physiological and pathological angiogenesis in the adult pulmonary circulation |
| Q28388425 | Pulmonary fibrosis: pathogenesis, etiology and regulation |
| Q36328903 | Pulmonary hypertension in parenchymal lung disease |
| Q36478639 | Remodeling of extra-bronchial lung vasculature following allergic airway inflammation |
| Q36120825 | Role of chemokines in tumor growth |
| Q28748540 | Serum amyloid P therapeutically attenuates murine bleomycin-induced pulmonary fibrosis via its effects on macrophages |
| Q30426561 | Spontaneous lung dysfunction and fibrosis in mice lacking connexin 40 and endothelial cell connexin 43 |
| Q33917582 | Static and dynamic mechanics of the murine lung after intratracheal bleomycin |
| Q41653958 | Targeting of Discoidin Domain Receptor 2 (DDR2) Prevents Myofibroblast Activation and Neovessel Formation During Pulmonary Fibrosis |
| Q33947213 | Targeting the cannabinoid pathway limits the development of fibrosis and autoimmunity in a mouse model of systemic sclerosis |
| Q62784096 | The Organotelluride Catalyst (PHTE)2NQ Prevents HOCl-Induced Systemic Sclerosis in Mouse |
| Q36970923 | The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis? |
| Q37691190 | The natural organosulfur compound dipropyltetrasulfide prevents HOCl-induced systemic sclerosis in the mouse |
| Q30443091 | The role of CXC chemokines in pulmonary fibrosis |
| Q30427773 | The role of fibrocytes in sickle cell lung disease |
| Q24812428 | The role of pro- and anti-inflammatory responses in silica-induced lung fibrosis |
| Q38003021 | Tissue microenvironments define and get reinforced by macrophage phenotypes in homeostasis or during inflammation, repair and fibrosis. |
| Q38068399 | Tissues use resident dendritic cells and macrophages to maintain homeostasis and to regain homeostasis upon tissue injury: the immunoregulatory role of changing tissue environments. |
| Q65556923 | Toxicological studies of (Misai Kucing) standardized ethanol extract in combination with gemcitabine in athymic nude mice model |
| Q36470465 | Update in diffuse parenchymal lung diseases 2005. |
Search more.